Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
about
New insights into treatment of osteoporosis in postmenopausal womenA review of denosumab for the treatment of osteoporosisSafety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysisObservations following discontinuation of long-term denosumab therapy.Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosisChinese bone turnover marker study: reference ranges for C-terminal telopeptide of type I collagen and procollagen I N-terminal peptide by age and gender.The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extensionFemoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab.Denosumab: A bone antiresorptive drugUpdate on denosumab treatment in postmenopausal women with osteoporosis.Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis.Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis.Chronic kidney disease and the skeleton.Management of severe osteoporosis.A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis.Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 yearsThe effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension studyClinical targeting of the TNF and TNFR superfamiliesThe contribution of cortical and trabecular tissues to bone strength: insights from denosumab studiesCan lumbar spine bone mineral density predict readmission in denosumab-treated patients with chronic kidney disease?Safety concerns with the long-term management of osteoporosis.A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.Periprosthetic osteolysis after total hip replacement: molecular pathology and clinical management.The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.Denosumab: a review of its use in postmenopausal women with osteoporosis.Locally limited inhibition of bone resorption and orthodontic relapse by recombinant osteoprotegerin protein.A complicated disease: what can be done to manage thalassemia major more effectively?How Long to Treat with Denosumab.New management options for osteoporosis with emphasis on SERMs.Spanish consensus on treat to target for osteoporosis.Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.New and emerging concepts in the use of denosumab for the treatment of osteoporosis
P2860
Q26777910-8F721CC5-ACB0-4009-9113-85E181CCC2CFQ27005894-B665BBD6-26E1-4A46-8353-B3D25991AF31Q28242783-35E8A82D-77A1-45CB-B8F7-6AF19EC130CFQ33563846-2AFF930B-634C-4889-8CD1-CA6DFB681D9EQ33663460-C7608408-1EEF-4EBA-89AD-92B62A2808E8Q34035048-D1A015C6-1EC0-4A26-820E-3B0D655F4FEFQ34396612-C77DAAD6-4523-4D94-B46B-B0C0FFBE4900Q34548650-C9892736-A759-4F35-89FB-44921334E7A1Q34980675-397469C6-3A71-4669-B8A0-75A1A7FCE5C3Q35260850-E854129E-9E96-46D4-A9C9-A31E65797DB7Q35589102-843A58FA-CAB2-4CDA-8D66-759513A4CEFFQ35689812-A65B805F-120A-4E02-AC64-C6D423AF6F03Q35755179-40664BB1-2A91-48BE-9AC2-E106070C9297Q35852252-5A4B281C-BE50-430E-B91B-6335C5E0DE9AQ36059455-E6090DA4-DED0-4ACF-8B32-579017FAF3EAQ36309349-2CC80DD7-D4BC-4169-8798-376D81BD8B19Q36309353-431845F7-066E-41E0-AFCF-82B9979BB501Q36762882-9AB46985-2E30-4AB7-9EFB-7D68F4A0706AQ37008054-52B062A2-EABD-48E6-863A-C6294F51F217Q37616992-5B916E4F-6A13-45BA-BF62-DD1A8CE3F11AQ38101363-6717C5FC-F46E-4AA2-B730-368043EAC277Q38138862-77503A39-70DD-474D-BA55-40E0D0E51D92Q38152730-C8A8DF6E-450B-4DF5-B609-55BA566BFA88Q38193181-73D92139-41FC-4D08-A1DC-C5237943D556Q38220743-83BDB504-AFFE-4F58-8517-DB0F7DE26FBAQ38414010-D6564DC4-8BC8-487F-9482-E85BEBA2D13EQ38607875-3CCE13A0-9265-47F4-8AD0-09C8A0C8156EQ38609225-FE6050E4-EC63-4F8F-8DD7-D450F1B11E4BQ38616755-4691535C-6C03-438C-B984-21D339EE72A7Q47596255-4AB3CD1B-A28F-472F-9832-C44D8C0548D3Q48276155-EC754B7F-58EE-4B37-8972-FF3034ACA1E5Q49630595-3D1329AA-8CFF-44A1-9128-C880441C7AD5Q58583955-ED932F05-545C-47B6-8B68-A92F9D0097DA
P2860
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Effect of denosumab on bone mi ...... ts of a phase 2 clinical trial
@ast
Effect of denosumab on bone mi ...... ts of a phase 2 clinical trial
@en
type
label
Effect of denosumab on bone mi ...... ts of a phase 2 clinical trial
@ast
Effect of denosumab on bone mi ...... ts of a phase 2 clinical trial
@en
prefLabel
Effect of denosumab on bone mi ...... ts of a phase 2 clinical trial
@ast
Effect of denosumab on bone mi ...... ts of a phase 2 clinical trial
@en
P2093
P2860
P1476
Effect of denosumab on bone mi ...... ts of a phase 2 clinical trial
@en
P2093
E M Lewiecki
E Rockabrand
M A Bolognese
M L Geller
P D Miller
R B Wagman
R L Weinstein
P2860
P2888
P304
P356
10.1007/S00198-012-2052-4
P407
P577
2012-07-10T00:00:00Z